O	0	10	Modulation	Modulation	NN	B-NP
O	11	13	of	of	IN	B-PP
O	14	23	apoptosis	apoptosis	NN	B-NP
O	24	26	in	in	IN	B-PP
O	27	32	human	human	JJ	B-NP
B-Cell	33	40	myeloid	myeloid	JJ	I-NP
I-Cell	41	49	leukemic	leukemic	JJ	I-NP
I-Cell	50	55	cells	cell	NNS	I-NP
O	56	58	by	by	IN	B-PP
O	59	61	GM	GM	NNP	B-NP
O	61	62	-	-	HYPH	O
O	62	65	CSF	CSF	NNP	B-NP
O	65	66	.	.	.	O

O	68	77	Apoptosis	Apoptosis	NN	B-NP
O	78	79	(	(	(	O
O	79	89	programmed	program	VBN	B-NP
B-Cell	90	94	cell	cell	NN	I-NP
O	95	100	death	death	NN	I-NP
O	100	101	)	)	)	O
O	102	111	regulates	regulate	VBZ	B-VP
B-Cell	112	116	cell	cell	NN	B-NP
O	117	127	population	population	NN	I-NP
O	128	132	size	size	NN	I-NP
O	132	133	.	.	.	O

O	134	136	To	To	TO	B-VP
O	137	146	determine	determine	VB	I-VP
O	147	150	the	the	DT	B-NP
O	151	161	mechanisms	mechanism	NNS	I-NP
O	162	169	whereby	whereby	WRB	B-ADVP
O	170	183	hematopoietic	hematopoietic	JJ	B-NP
O	184	190	growth	growth	NN	I-NP
O	191	198	factors	factor	NNS	I-NP
O	199	200	(	(	(	O
O	200	204	HGFs	HGF	NNS	B-NP
O	204	205	)	)	)	O
O	206	214	modulate	modulate	VBP	B-VP
O	215	224	apoptosis	apoptosis	NN	B-NP
O	225	227	in	in	IN	B-PP
O	228	233	human	human	JJ	B-NP
B-Cell	234	241	myeloid	myeloid	JJ	I-NP
I-Cell	242	250	leukemic	leukemic	JJ	I-NP
I-Cell	251	256	cells	cell	NNS	I-NP
O	256	257	,	,	,	O
O	258	260	we	we	PRP	B-NP
O	261	270	evaluated	evaluate	VBD	B-VP
O	271	274	the	the	DT	B-NP
O	275	280	roles	role	NNS	I-NP
O	281	283	of	of	IN	B-PP
O	284	291	protein	protein	NN	B-NP
O	292	295	and	and	CC	O
O	296	300	mRNA	mRNA	NN	B-NP
O	301	310	synthesis	synthesis	NN	I-NP
O	311	314	for	for	IN	B-PP
O	315	323	altering	alter	VBG	B-VP
O	324	333	apoptosis	apoptosis	NN	B-NP
O	334	336	in	in	IN	B-PP
O	337	343	growth	growth	NN	B-NP
O	344	350	factor	factor	NN	I-NP
O	350	351	-	-	HYPH	B-NP
O	351	361	stimulated	stimulate	VBN	I-NP
O	362	364	vs	v	NNS	I-NP
O	364	365	.	.	.	O
O	366	375	quiescent	quiescent	JJ	B-NP
B-Cell	376	384	leukemic	leukemic	JJ	I-NP
I-Cell	385	388	TF1	TF1	NN	I-NP
I-Cell	389	394	cells	cell	NNS	I-NP
O	394	395	.	.	.	O

B-Organism_substance	396	403	Lysates	Lysate	NNS	B-NP
O	404	406	of	of	IN	B-PP
B-Cell	407	412	cells	cell	NNS	B-NP
O	413	417	from	from	IN	B-PP
O	418	421	the	the	DT	B-NP
O	422	433	granulocyte	granulocyte	NN	I-NP
O	433	434	-	-	HYPH	O
O	434	444	macrophage	macrophage	NN	B-NP
O	445	451	colony	colony	NN	I-NP
O	451	452	-	-	HYPH	O
O	452	463	stimulating	stimulate	VBG	B-VP
O	464	470	factor	factor	NN	B-NP
O	471	472	(	(	(	O
O	472	474	GM	GM	NN	B-NP
O	474	475	-	-	HYPH	B-NP
O	475	478	CSF	CSF	NN	I-NP
O	478	479	)	)	)	O
O	479	480	-	-	HYPH	B-NP
O	480	489	dependent	dependent	JJ	I-NP
B-Cell	490	497	myeloid	myeloid	JJ	I-NP
I-Cell	498	506	leukemic	leukemic	JJ	I-NP
I-Cell	507	511	cell	cell	NN	I-NP
I-Cell	512	516	line	line	NN	I-NP
I-Cell	517	520	TF1	TF1	NN	I-NP
O	521	525	were	be	VBD	B-VP
O	526	535	separated	separate	VBN	I-VP
O	536	540	into	into	IN	B-PP
O	541	545	high	high	JJ	B-NP
O	546	555	molecular	molecular	JJ	I-NP
O	556	562	weight	weight	NN	I-NP
O	563	564	(	(	(	O
O	564	567	HMW	HMW	NN	B-NP
O	567	568	)	)	)	O
O	569	576	pellets	pellet	NNS	B-NP
O	577	579	of	of	IN	B-PP
O	580	586	intact	intact	JJ	B-NP
O	587	590	DNA	DNA	NN	I-NP
O	591	594	and	and	CC	O
B-Organism_substance	595	607	supernatants	supernatant	NNS	B-NP
O	608	610	of	of	IN	B-PP
O	611	621	fragmented	fragmented	JJ	B-NP
O	622	625	low	low	JJ	I-NP
O	626	628	MW	MW	NN	I-NP
O	629	630	(	(	(	O
O	630	633	LMW	LMW	NN	B-NP
O	633	634	)	)	)	O
O	635	638	DNA	DNA	NN	B-NP
O	638	639	,	,	,	O
O	640	643	and	and	CC	O
O	644	647	the	the	DT	B-NP
O	648	651	DNA	DNA	NN	I-NP
O	652	660	purified	purify	VBN	B-VP
O	661	665	from	from	IN	B-PP
O	666	671	these	these	DT	B-NP
O	672	681	fractions	fraction	NNS	I-NP
O	682	685	was	be	VBD	B-VP
O	686	696	quantified	quantify	VBN	I-VP
O	696	697	.	.	.	O

O	698	700	In	In	IN	B-PP
O	701	704	the	the	DT	B-NP
O	705	712	absence	absence	NN	I-NP
O	713	715	of	of	IN	B-PP
O	716	720	both	both	CC	O
O	721	723	GM	GM	NNP	B-NP
O	723	724	-	-	HYPH	B-NP
O	724	727	CSF	CSF	NN	I-NP
O	728	731	and	and	CC	O
B-Organism_substance	732	737	fetal	fetal	JJ	B-NP
I-Organism_substance	738	744	bovine	bovine	JJ	I-NP
I-Organism_substance	745	750	serum	serum	NN	I-NP
O	751	752	(	(	(	O
B-Organism_substance	752	755	FBS	FBS	NN	B-NP
O	755	756	)	)	)	O
O	756	757	,	,	,	O
O	758	760	70	70	CD	B-NP
O	760	761	%	%	NN	I-NP
O	762	764	of	of	IN	B-PP
O	765	768	the	the	DT	B-NP
O	769	772	DNA	DNA	NN	I-NP
O	773	776	was	be	VBD	B-VP
O	777	787	fragmented	fragment	VBN	I-VP
O	788	793	after	after	IN	B-PP
O	794	795	3	3	CD	B-NP
O	796	800	days	day	NNS	I-NP
O	801	803	in	in	IN	B-PP
O	804	811	culture	culture	NN	B-NP
O	811	812	,	,	,	O
O	813	817	with	with	IN	B-PP
O	818	819	a	a	DT	B-NP
O	820	834	characteristic	characteristic	JJ	I-NP
O	835	844	apoptotic	apoptotic	JJ	I-NP
O	845	851	ladder	ladder	NN	I-NP
O	851	852	-	-	HYPH	B-NP
O	852	856	like	like	JJ	I-NP
O	857	864	pattern	pattern	NN	I-NP
O	865	867	on	on	IN	B-PP
O	868	875	agarose	agarose	NN	B-NP
O	876	879	gel	gel	NN	I-NP
O	880	895	electrophoresis	electrophoresis	NN	I-NP
O	895	896	,	,	,	O
O	897	904	whereas	whereas	IN	O
O	905	909	this	this	DT	B-NP
O	910	920	proportion	proportion	NN	I-NP
O	921	924	had	have	VBD	B-VP
O	925	934	initially	initially	RB	I-VP
O	935	939	been	be	VBN	I-VP
O	940	941	<	<	JJR	B-NP
O	942	943	5	5	CD	I-NP
O	943	944	%	%	NN	I-NP
O	944	945	.	.	.	O

O	946	948	In	In	IN	B-PP
O	949	957	contrast	contrast	NN	B-NP
O	957	958	,	,	,	O
O	959	963	less	less	JJR	B-NP
O	964	968	than	than	IN	I-NP
O	969	970	5	5	CD	I-NP
O	970	971	%	%	NN	I-NP
O	972	974	of	of	IN	B-PP
O	975	978	the	the	DT	B-NP
O	979	982	DNA	DNA	NN	I-NP
O	983	986	was	be	VBD	B-VP
O	987	997	fragmented	fragment	VBN	I-VP
O	998	1000	in	in	IN	B-PP
B-Cell	1001	1006	cells	cell	NNS	B-NP
O	1007	1016	incubated	incubate	VBN	B-VP
O	1017	1021	with	with	IN	B-PP
O	1022	1024	GM	GM	NNP	B-NP
O	1024	1025	-	-	HYPH	I-NP
O	1025	1028	CSF	CSF	NNP	I-NP
O	1029	1033	plus	plus	CC	O
B-Organism_substance	1034	1037	FBS	FBS	NNP	B-NP
O	1038	1040	or	or	CC	I-NP
O	1041	1043	GM	GM	NNP	I-NP
O	1043	1044	-	-	HYPH	I-NP
O	1044	1047	CSF	CSF	NN	I-NP
O	1048	1053	alone	alone	RB	B-ADVP
O	1053	1054	.	.	.	O

O	1055	1062	Delayed	Delay	VBN	B-NP
O	1063	1071	addition	addition	NN	I-NP
O	1072	1074	of	of	IN	B-PP
O	1075	1077	GM	GM	NNP	B-NP
O	1077	1078	-	-	HYPH	I-NP
O	1078	1081	CSF	CSF	NN	I-NP
O	1081	1082	,	,	,	O
O	1083	1086	but	but	CC	O
O	1087	1090	not	not	RB	O
B-Organism_substance	1091	1094	FBS	FBS	NNP	B-NP
O	1094	1095	,	,	,	O
O	1096	1105	permitted	permit	VBD	B-VP
O	1106	1113	partial	partial	JJ	B-NP
O	1114	1120	rescue	rescue	NN	I-NP
O	1121	1123	of	of	IN	B-PP
O	1124	1127	the	the	DT	B-NP
B-Cell	1128	1133	cells	cell	NNS	I-NP
O	1133	1134	,	,	,	O
O	1135	1145	inhibiting	inhibit	VBG	B-VP
O	1146	1156	increasing	increase	VBG	B-NP
O	1157	1162	rates	rate	NNS	I-NP
O	1163	1165	of	of	IN	B-PP
O	1166	1178	accumulation	accumulation	NN	B-NP
O	1179	1181	of	of	IN	B-PP
O	1182	1192	fragmented	fragmented	JJ	B-NP
O	1193	1196	DNA	DNA	NN	I-NP
O	1196	1197	.	.	.	O

O	1198	1202	When	When	WRB	B-ADVP
O	1203	1206	the	the	DT	B-NP
O	1207	1212	macro	macro	AFX	I-NP
O	1212	1213	-	-	HYPH	I-NP
O	1213	1222	molecular	molecular	JJ	I-NP
O	1223	1232	synthesis	synthesis	NN	I-NP
O	1233	1242	inhibitor	inhibitor	NN	I-NP
O	1243	1256	cycloheximide	cycloheximide	NN	I-NP
O	1257	1258	(	(	(	O
O	1258	1261	CHX	CHX	NN	B-NP
O	1261	1262	)	)	)	O
O	1263	1265	or	or	CC	O
O	1266	1277	actinomycin	actinomycin	NN	B-NP
O	1278	1279	D	D	NN	I-NP
O	1280	1281	(	(	(	O
O	1281	1284	Act	Act	NN	B-NP
O	1285	1286	D	D	NN	I-NP
O	1286	1287	)	)	)	O
O	1288	1291	was	be	VBD	B-VP
O	1292	1299	present	present	JJ	B-ADJP
O	1300	1303	for	for	IN	B-PP
O	1304	1306	26	26	CD	B-NP
O	1307	1312	hours	hour	NNS	I-NP
O	1313	1315	in	in	IN	B-PP
O	1316	1319	the	the	DT	B-NP
O	1320	1327	absence	absence	NN	I-NP
O	1328	1330	of	of	IN	B-PP
O	1331	1333	GM	GM	NNP	B-NP
O	1333	1334	-	-	HYPH	I-NP
O	1334	1337	CSF	CSF	NN	I-NP
O	1338	1341	and	and	CC	I-NP
B-Organism_substance	1342	1345	FBS	FBS	NN	I-NP
O	1345	1346	,	,	,	O
O	1347	1356	apoptosis	apoptosis	NN	B-NP
O	1357	1360	was	be	VBD	B-VP
O	1361	1370	inhibited	inhibit	VBN	I-VP
O	1370	1371	.	.	.	O

O	1372	1374	In	In	IN	B-PP
O	1375	1383	contrast	contrast	NN	B-NP
O	1383	1384	,	,	,	O
O	1385	1387	in	in	IN	B-PP
O	1388	1391	the	the	DT	B-NP
O	1392	1400	presence	presence	NN	I-NP
O	1401	1403	of	of	IN	B-PP
O	1404	1406	GM	GM	NNP	B-NP
O	1406	1407	-	-	HYPH	B-NP
O	1407	1410	CSF	CSF	NN	I-NP
O	1411	1413	or	or	CC	I-NP
B-Organism_substance	1414	1417	FBS	FBS	NN	I-NP
O	1417	1418	,	,	,	O
O	1419	1428	apoptosis	apoptosis	NN	B-NP
O	1429	1432	was	be	VBD	B-VP
O	1433	1441	enhanced	enhance	VBN	I-VP
O	1442	1446	upon	upon	IN	B-PP
O	1447	1455	addition	addition	NN	B-NP
O	1456	1458	of	of	IN	B-PP
O	1459	1462	CHX	CHX	NN	B-NP
O	1463	1465	or	or	CC	I-NP
O	1466	1469	Act	Act	NN	I-NP
O	1470	1471	D	D	NN	I-NP
O	1471	1472	.	.	.	O

O	1473	1476	The	The	DT	B-NP
O	1477	1483	latter	latter	JJ	I-NP
O	1484	1490	effect	effect	NN	I-NP
O	1491	1500	persisted	persist	VBD	B-VP
O	1501	1505	even	even	RB	B-ADVP
O	1506	1510	with	with	IN	B-PP
O	1511	1514	the	the	DT	B-NP
O	1515	1519	late	late	JJ	I-NP
O	1520	1528	addition	addition	NN	I-NP
O	1529	1531	of	of	IN	B-PP
O	1532	1535	CHX	CHX	NN	B-NP
O	1535	1536	.	.	.	O

O	1537	1542	These	These	DT	B-NP
O	1543	1551	findings	finding	NNS	I-NP
O	1552	1560	indicate	indicate	VBP	B-VP
O	1561	1565	that	that	IN	B-SBAR
O	1566	1575	disparate	disparate	JJ	B-NP
O	1576	1586	mechanisms	mechanism	NNS	I-NP
O	1587	1589	of	of	IN	B-PP
O	1590	1599	enhancing	enhance	VBG	B-VP
O	1600	1602	or	or	CC	I-VP
O	1603	1613	inhibiting	inhibit	VBG	I-VP
O	1614	1623	apoptosis	apoptosis	NN	B-NP
O	1624	1629	exist	exist	NN	I-NP
O	1630	1632	in	in	IN	B-PP
B-Cell	1633	1640	myeloid	myeloid	JJ	B-NP
I-Cell	1641	1649	leukemic	leukemic	JJ	I-NP
I-Cell	1650	1655	cells	cell	NNS	I-NP
O	1656	1663	related	relate	VBN	B-VP
O	1664	1666	to	to	TO	B-PP
O	1667	1680	environmental	environmental	JJ	B-NP
O	1681	1691	conditions	condition	NNS	I-NP
O	1691	1692	,	,	,	O
O	1693	1702	including	include	VBG	B-PP
O	1703	1706	HGF	HGF	NN	B-NP
O	1706	1707	-	-	HYPH	O
O	1707	1716	regulated	regulate	VBN	B-VP
B-Cell	1717	1725	cellular	cellular	JJ	B-NP
O	1726	1735	synthesis	synthesis	NN	I-NP
O	1736	1738	of	of	IN	B-PP
O	1739	1747	distinct	distinct	JJ	B-NP
O	1748	1756	proteins	protein	NNS	I-NP
O	1757	1760	and	and	CC	O
O	1761	1765	mRNA	mRNA	NN	B-NP
O	1765	1766	.	.	.	O

